ATAI
demonstrated safety level and plasma concentrations of in line with previous trials phase study trial design results summary | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2023
Slide
20 of 31
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
January 2024
demonstrated safety level and plasma concentrations of in line with previous trials potential therapeutic plasma levels no serious adverse events reported asymptomatic prolongation phase study trial design results summary | ATAI
Related slides by other companies
Hepion Pharmaceuticals
Results
October 2022
phase studies completed safe and well tolerated key findings | Hepion Pharmaceuticals
AstraZeneca
Investor Day
September 2022
supports further indication expansion | AstraZeneca
Equillium
Investor Presentation
December 2023
phase study of in adults with moderate to severe target product profile alternative to with at least comparable efficacy patient administered weekly weekly subcutaneous injection similar to | Equillium
Taysha
IPO
September 2020
preliminary animal studies demonstrated i | Taysha
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Conference
May 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights